W
WAVEMAN · COMPANY
INMB · Inmune Bio, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

INMB

Inmune Bio, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001711754
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
49
13F, latest reported quarter
REVENUE GROWTH
+257.1%
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
3
codes C/M, not in net · $43.4K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
49 funds added or opened last quarter
below 56% of Pharma & Biotech
REVENUE
+257.1% year over year
more than 91% of Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
7.9% of shares outstanding short · 6.6 days to cover · settled 2026-07-31
more than 69% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
49 funds added or opened positions in the latest 13F quarter, of 84 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +15.2%
+15.2%12M
-43%-21%+2%+24%2025-092025-102025-122026-032026-052026-072026-09
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 49 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Inmune Bio, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Moss David J
Chief Financial Officer
BUY
2024-09-30
10,000.0
$52.9K
Tesi Raymond Joseph
President and CEO
BUY
2024-09-12
15,380.0
$98.1K
Moss David J
Chief Financial Officer
BUY
2024-09-12
7,690.0
$49.1K
Juda Scott
Director
BUY
2024-06-25
5,000.0
$36.4K
Moss David J
CFO, Treasurer & Secretary
BUY
2024-04-19
18,028.0
$150.0K
33 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 28 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
VANGUARD CAPITAL MANAGEMENT LLC
706,424.0 sh
$1.2M
AQR CAPITAL MANAGEMENT LLC
662,218.0 sh
$1.1M
BlackRock, Inc.
311,613.0 sh
$507.9K
RAYMOND JAMES FINANCIAL INC
212,995.0 sh
$347.2K
GEODE CAPITAL MANAGEMENT, LLC
190,215.0 sh
$310.3K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
iShares Micro-Cap ETF
$64.5K POSITION · AS OF 2026-03-31
0.0%
Small Cap Core Fund
$13.1K POSITION · AS OF 2026-03-31
0.0%
PD Small-Cap Growth Index Portfolio
$3.6K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$4.0K POSITION · AS OF 2026-03-31
0.0%
iShares Russell 2000 Growth ETF
$227.9K POSITION · AS OF 2026-03-31
0.0%
Fidelity Small Cap Growth Index Fund
$19.5K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 7 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
2
Phase 1
0 ACTIVE
3
Phase 2
0 ACTIVE
2
Multi-phase
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$50.0K$14.0K$155.0K$374.0K
OPERATING INCOME$-47.4M$-42.6M$-29.7M$-26.0M
NET INCOME$-46.0M$-42.0M$-30.0M$-27.3M
EPS (DILUTED)-1.86-2.11-1.67-1.52
OPERATING CASH FLOW$-22.6M$-33.4M$-12.0M$-22.7M
CASH$24.8M$20.9M$35.8M$52.2M
LONG-TERM DEBT—$15.0M—$9.7M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →